首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >Coexistence of TSH-secreting pituitary adenoma and autoimmune hypothyroidism.
【24h】

Coexistence of TSH-secreting pituitary adenoma and autoimmune hypothyroidism.

机译:分泌 TSH 的垂体腺瘤和自身免疫性甲状腺功能减退症共存。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: TSH-secreting pituitary adenomas account for about 1-2 of all pituitary adenomas. Their diagnosis may be very difficult when coexistence of other diseases masquerades the clinical and biochemical manifestations of TSH-hypersecretion. CLINICAL PRESENTATION: A 41-yr-old female patient, weighing 56 kg, was referred for evaluation of an intra- and suprasellar mass causing menstrual irregularities. Eight yr before, the patient had been given a diagnosis of subclinical autoimmune hypothyroidism because of slightly elevated TSH levels and low-normal free T4 (FT4). Menses were normal. Despite increasing doses of levo-T4 (L-T4; up to 125 microg/day), TSH levels remained elevated and the patient developed mild symptoms of hyperthyroidism. After 7 yr, the menstrual cycle ceased. Gonadotropins were normal, whereas PRL level was elevated at 70 microg/l and magnetic resonance imaging (MRI) of the hypothalamic- pituitary region revealed a pituitary lesion with slight suprasellar extension. The tumor was surgically removed and histological examinations revealed a pituitary adenoma strongly positive for TSH. Three months after surgery the patient was well while receiving L-T4 75 microg/day and normal menses had resumed. MRI of the hypothalamic-pituitary region showed no evidence of residual tumor. At the last follow-up, 16 months after surgery, serum TSH, free T3 (FT3), and FT4 levels were normal. CONCLUSIONS: Coexistence of autoimmune hypothyroidism and TSH-secreting pituitary adenoma may cause further delays in the diagnosis of the latter. In patients with autoimmune hypothyroidism, one should be aware of the possible presence of a TSH-secreting pituitary adenoma when TSH levels do not adequately suppress in the face of high doses of L-T4 replacement therapy and elevated serum thyroid hormone levels.
机译:目的:分泌TSH的垂体腺瘤约占所有垂体腺瘤的1-2%。当其他疾病共存掩盖了TSH分泌过多的临床和生化表现时,它们的诊断可能非常困难。临床表现:一名 41 岁女性患者,体重 56 kg,因导致月经不调的鞍内和鞍上肿块被转诊评估。8 年前,由于 TSH 水平略有升高和正常游离 T4 (FT4) 水平低下,患者被诊断为亚临床自身免疫性甲状腺功能减退症。月经正常。尽管左旋-T4(L-T4;高达125微克/天)的剂量增加,但TSH水平仍然升高,患者出现甲状腺功能亢进的轻度症状。7年后,月经周期停止。促性腺激素正常,PRL水平升高至70μg/l,下丘脑-垂体区域磁共振成像(MRI)显示垂体病变伴轻微鞍上延伸。手术切除肿瘤,组织学检查显示垂体腺瘤 TSH 强烈阳性。手术后三个月,患者在接受 L-T4 75 微克/天治疗时身体状况良好,月经恢复正常。下丘脑-垂体区域的 MRI 未显示残留肿瘤的证据。在最后一次随访时,术后 16 个月,血清 TSH、游离 T3 (FT3) 和 FT4 水平正常。结论:自身免疫性甲状腺功能减退症和分泌TSH的垂体腺瘤的共存可能导致后者的诊断进一步延迟。在自身免疫性甲状腺功能减退症患者中,当面对高剂量的 L-T4 替代疗法和血清甲状腺激素水平升高时,当 TSH 水平不能充分抑制时,应注意可能存在分泌 TSH 的垂体腺瘤。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号